Can atomoxetine be used in patients with cardiac disorders?

Atomoxetine Use in Patients with Cardiac Disorders

Atomoxetine should not be used in patients with severe cardiac disorders, but may be cautiously considered in patients with mild to moderate cardiac conditions under close monitoring.

Contraindications and Cardiac Risk Assessment

Atomoxetine is absolutely contraindicated in patients with:

• Severe cardiovascular disorders whose condition would be expected to deteriorate with increases in blood pressure or heart rate 1
• Pheochromocytoma or history of pheochromocytoma 1
• Narrow angle glaucoma 1

For all other patients with cardiac conditions, a thorough cardiac risk assessment is necessary before considering atomoxetine:

• Obtain detailed personal and family cardiac history, particularly focusing on:

  • Sudden cardiac death
  • Cardiovascular symptoms
  • Wolff-Parkinson-White syndrome
  • Hypertrophic cardiomyopathy
  • Long QT syndrome 2

• If any cardiac risk factors are present, perform an ECG and consider referral to a cardiologist if the ECG is abnormal 2

Cardiovascular Effects of Atomoxetine

Atomoxetine has demonstrated cardiovascular effects that require consideration:

• Small but statistically significant increases in blood pressure (particularly systolic in adults, diastolic in children/adolescents) 3
• Mild increases in heart rate across all age groups 3, 4
• These changes typically occur early in therapy, stabilize over time, and return toward baseline upon discontinuation 3
• Unlike stimulants, atomoxetine does not cause QT interval prolongation 3

Decision Algorithm for Atomoxetine Use in Cardiac Patients

1. Severe cardiac conditions: Absolutely contraindicated 1

   • Conditions where increases in BP (15-20 mmHg) or HR (20 bpm) would cause clinical deterioration

2. Moderate cardiac conditions:

   • Consider alternative non-stimulant options first (guanfacine, clonidine) 5
   • If atomoxetine is necessary, implement:
     • Baseline ECG
     • Cardiology consultation
     • Regular BP and HR monitoring (weekly initially, then monthly)
     • Lower starting dose (0.5 mg/kg/day) with slower titration 5

3. Mild cardiac conditions:

   • May use atomoxetine with caution
   • Regular monitoring of vital signs
   • Start at lower doses and titrate slowly

Monitoring Recommendations

For patients with cardiac disorders who are prescribed atomoxetine:

• Monitor vital signs before treatment initiation and regularly during treatment
• Schedule more frequent monitoring during dose adjustments
• Watch for cardiovascular adverse events, particularly palpitations (reported in 3.7% of adult patients vs 0.8% with placebo) 3
• Consider periodic ECG monitoring in patients with pre-existing cardiac conditions
• Discontinue if clinically significant increases in HR or BP occur

Special Considerations

• Atomoxetine may be preferred over stimulants in patients with cardiac concerns, as studies suggest pre-existing cardiovascular conditions reduce the likelihood of stimulant therapy but not atomoxetine treatment in adult ADHD patients 6
• The risk of serious cardiovascular events with atomoxetine is extremely low at therapeutic doses 4
• A large study of ADHD medication initiators found no increased risk of heart failure or cardiomyopathy with longer-term use of ADHD medications, including atomoxetine 7

Clinical Pearls and Pitfalls

• Avoid combining atomoxetine with MAOIs due to risk of serious reactions including hyperthermia, autonomic instability, and mental status changes 1
• Be aware that atomoxetine is primarily metabolized through CYP2D6, and some SSRIs can elevate serum atomoxetine levels 8
• Poor metabolizers of atomoxetine (approximately 7% of the population) may experience higher plasma levels and more adverse effects 8
• Atomoxetine has a delayed onset of action (6-12 weeks), which should be considered when selecting treatment options 5

By following these guidelines, clinicians can make informed decisions about the use of atomoxetine in patients with cardiac disorders, balancing the benefits of ADHD treatment against potential cardiovascular risks.